PT87273A - Process for preparing substituted quinolones - Google Patents

Process for preparing substituted quinolones

Info

Publication number
PT87273A
PT87273A PT87273A PT8727388A PT87273A PT 87273 A PT87273 A PT 87273A PT 87273 A PT87273 A PT 87273A PT 8727388 A PT8727388 A PT 8727388A PT 87273 A PT87273 A PT 87273A
Authority
PT
Portugal
Prior art keywords
preparing substituted
substituted quinolones
quinolones
preparing
substituted
Prior art date
Application number
PT87273A
Other languages
English (en)
Inventor
Simon Frazer Campbell
David Stuart Morris
David Anthony Roberts
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PT87273A publication Critical patent/PT87273A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT87273A 1987-04-21 1988-04-19 Process for preparing substituted quinolones PT87273A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878709448A GB8709448D0 (en) 1987-04-21 1987-04-21 Heterobicyclic quinoline derivatives

Publications (1)

Publication Number Publication Date
PT87273A true PT87273A (pt) 1988-05-01

Family

ID=10616116

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87273A PT87273A (pt) 1987-04-21 1988-04-19 Process for preparing substituted quinolones

Country Status (7)

Country Link
US (1) US4898872A (pt)
EP (1) EP0290153A1 (pt)
JP (1) JPS63280078A (pt)
DK (1) DK214088A (pt)
FI (1) FI881825A (pt)
GB (1) GB8709448D0 (pt)
PT (1) PT87273A (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1991012251A1 (en) * 1990-02-19 1991-08-22 Chugai Seiyaku Kabushiki Kaisha Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2333643A1 (en) * 1998-06-30 2000-01-06 James D. Rodgers Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6528649B2 (en) 2000-05-30 2003-03-04 Neurogen Corporation Imidazoloisoquinolines
WO2002018383A2 (en) 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
ES2302106T3 (es) * 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina.
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
EP2174933B1 (en) * 2003-03-13 2019-04-03 Idemitsu Kosan Co., Ltd. Benzimidazole derivatives for use in organic electroluminescent devices
RU2377988C2 (ru) 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Модуляция воспалительных и метастатических процессов
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2580852A1 (en) * 2004-09-21 2006-03-30 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
AU2006247803B2 (en) 2005-05-13 2011-12-22 Novartis Ag Methods for treating drug resistant cancer
BRPI0610355A2 (pt) 2005-05-17 2010-06-15 Novartis Ag métodos par sintetizar compostos heterocìclicos
AU2006249847B2 (en) 2005-05-23 2012-12-20 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
ATE543819T1 (de) * 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
EP2348018A4 (en) 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYLIC DERIVATIVE AND PDE INHIBITOR COMPRISING THE SAME AS ACTIVE INGREDIENT
US20110224250A1 (en) * 2008-10-09 2011-09-15 Yasushi Kohno Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
US9353081B2 (en) 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
ES2894958T3 (es) 2011-10-19 2022-02-16 Signal Pharm Llc Tratamiento del cáncer con inhibidores de la quinasa TOR
KR102040997B1 (ko) 2011-12-02 2019-11-27 시그날 파마소티칼 엘엘씨 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP3202403A1 (en) 2013-01-16 2017-08-09 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JP6382949B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法
CN105324381A (zh) 2013-04-17 2016-02-10 西格诺药品有限公司 有关1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1H)-酮的药物制剂、程序、固体形式和使用方法
JP6382945B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
KR20160002792A (ko) 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
TWI631949B (zh) 2013-04-17 2018-08-11 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
TWI656875B (zh) 2013-04-17 2019-04-21 美商標誌製藥公司 藉二氫吡并吡治療癌症
JPWO2014174745A1 (ja) * 2013-04-26 2017-02-23 国立大学法人京都大学 Ｅｇ５阻害剤
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US9623028B2 (en) 2014-07-14 2017-04-18 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
JP6702956B2 (ja) 2014-10-10 2020-06-03 サビック グローバル テクノロジーズ ベスローテン フェンノートシャップ ポリエーテルイミドワニス組成物、その製造方法およびそれから製造される物品
WO2018237114A1 (en) 2017-06-22 2018-12-27 Celgene Corporation TREATMENT OF HEPATOCELLULAR CARCINOMA CHARACTERIZED BY HEPATITIS B VIRUS INFECTION
EP3679028A1 (en) * 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) * 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
JPS5782390A (en) * 1980-11-11 1982-05-22 Otsuka Pharmaceut Co Ltd Carbostyril derivative
FI77852C (fi) * 1981-02-17 1989-05-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av nya, saosom hjaertmediciner anvaendbara substituerade amid- och (maettad heterocykel)karbonylkarbostyrilderivat.
US4710507A (en) * 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
ES8608874A1 (es) * 1984-05-29 1986-09-01 Pfizer Un procedimiento para la preparacion de una 2-(1h)-quinolona
GB8502267D0 (en) * 1985-01-30 1985-02-27 Pfizer Ltd Quinolone inotropic agents
JPH0662608B2 (ja) * 1985-08-26 1994-08-17 大塚製薬株式会社 カルボスチリル誘導体
GB8529362D0 (en) * 1985-11-28 1986-01-02 Pfizer Ltd Quinolone cardiac stimulants
JPS63301821A (ja) * 1986-03-05 1988-12-08 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JPH07121937B2 (ja) * 1987-03-18 1995-12-25 大塚製薬株式会社 カルボスチリル誘導体

Also Published As

Publication number Publication date
GB8709448D0 (en) 1987-05-28
EP0290153A1 (en) 1988-11-09
DK214088D0 (da) 1988-04-20
FI881825A (fi) 1988-10-22
FI881825A0 (fi) 1988-04-19
US4898872A (en) 1990-02-06
DK214088A (da) 1988-12-07
JPS63280078A (ja) 1988-11-17

Similar Documents

Publication Publication Date Title
PT87273A (pt) Process for preparing substituted quinolones
PT86866A (pt) Process for preparing piperazinyl-heterocyclic compounds
PT88596A (pt) Process for preparing 2-anilinopyrimidine derivatives useful aspesticidas
FI882007A0 (fi) Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi
ES543653A0 (es) Procedimiento de preparar derivados de 1,4-dihidropiridinas
DK101492A (da) Quinolinderivater
DK439688D0 (da) Quinoloner
NO172447C (no) Fremgangsmaate for fremstilling av b-avermectiner
PT87218A (pt) Process for preparing substituted pyrroles
NO885607L (no) Fremgangsmaate for fremstilling av piperidinylforbindelser.
PT87564A (pt) Process for preparing substituted vinylcephalosporins useful as medicaments
FI885045A0 (fi) Menetelmä polynukleotidien valmistamiseksi
NO883339D0 (no) Fremgangsmaate for fremstilling av benzimidazol-2-yl-pyridiniumforbindelser.
PT87489A (pt) Process for preparing oximinio ether compounds
DE3465987D1 (de) Process for preparing azetidinone derivatives
RO82034A (ro) Procedeu pentru prepararea 3-picolinei
DE3464910D1 (de) Process for preparing pyrimidinetrione derivatives
PT86829A (pt) Process for preparing thienothiopyran derivatives
PT87779A (pt) Process for preparing substituted penem compounds
DE3463140D1 (de) Process for preparing azetidinone derivatives
IT8422800A1 (it) Procedimento per preparare arilalchilchetoni
DE3275719D1 (de) Process for preparing omega-fluorosulfato-perfluoroalcanoic-acid derivatives
PT88407A (pt) Process for preparing azolidinedione derivatives
PT86936A (pt) Process for preparing fluoxirane carboxylates
DE3372613D1 (de) Process for preparing azetidinone derivatives

Legal Events

Date Code Title Description
FC3A Refusal

Effective date: 19920714